Half Year 2024 Kuros Biosciences AG Earnings Call Transcript
Okay, as people are coming into the meeting, I want to say good morning, good afternoon, depending upon your location. And welcome to the first half earnings, the strategic update for Kuros Biosciences. My name is Chris Fair, I'm the CEO. And I'll be joined by Daniel and Joost, CFO and Founder; Joost, President of Innovation, as we discuss the first half earnings update and look forward.
Next slide. This disclaimer will highlight -- and you can read it in its entirety when it's posted online, but this is a disclaimer that we will be discussing forward-looking statements.
Next slide. We are extremely excited to announce our first half results as an organization. When we look back at the past six months of the organization, we have clearly positioned ourselves as a high-growth MedTech business. We have derisked the business from our transition of the Fibrin-PTH platform, and as well as looking at our MagnetOs platform. And with recently published Level 1 evidence and our commercial execution, it has
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
